The Next Wave Of Weight-Loss Drugs Is Here—And It Targets Three Hormones, Not One

Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most ...
Life & Style on MSN

Why Experts Say This New Weight Loss Drug Could Be a Game Changer

Retatrutide, a new experimental weight-loss drug, targets three hormones and shows promising results far beyond current ...

Is Eli Lilly a Buy Before 2026?

Eli Lilly’s next-generation obesity treatment may prove highly effective for patients who have high BMI or suffer from ...
Self Employed on MSN

Retatrutide targets three gut hormones

Retatrutide targets three key pathways linked to appetite, metabolism, and energy use: GLP-1, GIP, and glucagon. GLP-1 and ...
MedPage Today on MSN

GLP-1 Microdosing and Longevity; Near 30% Weight Loss in Trial; 2025's Top Research

Meanwhile, people with overweight or obesity lost up to 11.3% more weight than placebo by week 36 with a novel GLP-1 agonist ...

Eli Lilly or Merck: Where Should Investors Put Their Money?

LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.

Eli Lilly Strengthens Market Position with Promising Trial Data and Dividend Boost

With a market capitalization approaching the $1 trillion mark, Eli Lilly is engaged in a close competitive race with Novo Nordisk for dominance in the obesity treatment sector. Market researchers ...

Neurocrine Biosciences, Inc. (NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs Transcript

Neurocrine Biosciences, Inc. ( NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs December 16, 2025 12:00 PM EST ...